skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.08d (Release date: 2017-08-28)
SearchBox Top
SearchBox Bottom
Alisertib (Code C71717)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Alisertib

Definition: A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Alisertib binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers, including colon and breast cancers.

Display Name: Alisertib

Label: Alisertib

NCI Thesaurus Code: C71717 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2346875  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Aurora A Kinase Inhibitor MLN8237
Benzoic Acid, 4-((9-Chloro-7-(2-Fluoro-6-Methoxyphenyl)-5H-Pyrimido(5,4-d)(2)Benzazepin-2-yl)Amino)-2-Methoxy-

External Source Codes: 
CAS Registry Number 1028486-01-2 (see NLM ChemIDplus info)
FDA UNII Code T66ES73M18
PDQ Closed Trial Search ID 561286
PDQ Open Trial Search ID 561286 (check for NCI PDQ open clinical trial info)
UMLS CUI C2346875

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C27H20ClFN4O4
code C71717
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Aurora_A_Kinase_Inhibitor_MLN8237
Semantic_Type Chemical Viewed Functionally

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom